Stock 2190 ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zylox-Tonbridge Medical Technology Co., Ltd.

Equities

2190

CNE100004JD2

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:28 2024-05-24 am EDT 		5-day change 1st Jan Change
10.4 HKD +1.17% Intraday chart for Zylox-Tonbridge Medical Technology Co., Ltd. -6.31% -16.40%
May. 09 Zylox-Tonbridge Medical Technology Co., Ltd. Announces Retirement of Hongze Liang as an Independent Non-Executive Director CI
Mar. 22 Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • With an expected P/E ratio at 47.27 and 21.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. Stock Zylox-Tonbridge Medical Technology Co., Ltd.
-16.40% 431M -
STRYKER CORPORATION Stock Stryker Corporation
+12.05% 128B
A-
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-9.24% 10.88B
A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+0.29% 8.76B
C
GLAUKOS CORPORATION Stock Glaukos Corporation
+36.99% 5.48B
B+
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
-21.98% 4.72B
C
AXONICS, INC. Stock Axonics, Inc.
+8.02% 3.43B
C-
ENOVIS CORPORATION Stock Enovis Corporation
-10.32% 2.76B
B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-12.33% 2.06B - -
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-13.53% 1.92B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2190 Stock
  4. Ratings Zylox-Tonbridge Medical Technology Co., Ltd.